The settlement agreement resolves all outstanding patent litigation relating to AUVELITY.

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

suggesting room for future upside. Axsome's products, particularly AXS-05, are positioned favorably in the competitive landscape of CNS therapeutics. The drug's differentiated safety profile and ...

Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $143.00. The company’s shares closed ...

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial ...

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

UBS analysts increased the price target on Axsome Therapeutics (NASDAQ:AXSM) shares to $133.00, up from the previous $105.00, while maintaining a Buy rating on the stock. The company, currently valued ...

Axsome Therapeutics, Inc. (NASDAQ ... This article provides a comprehensive analysis of Axsome's current position, future prospects, and potential challenges in the competitive CNS drug market.

Beyond AXS-05 and AUVELITY, Axsome has a robust pipeline that could drive future growth. AXS-07 for acute migraine ... In conclusion, Axsome Therapeutics presents a compelling investment case with its ...

Short interest in Axsome Therapeutics Inc (NASDAQ:AXSM) decreased during the last reporting period, falling from 6.62M to 5.75M. This put 14.22% of the company's publicly available shares short.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...